Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 607

The DOI matches its Crossref record.

Primary Chemotherapy To Avoid Mastectomy in Tumors With Diameters of Three Centimeters or More

Bonadonna, G., Veronesi, U., Brambilla, C., Ferrari, L., Luini, A., Greco, M., Bartoli, C., Yoldi, G. C. d., Zucali, R., Rilke, F., Andreola, S., Silvestrini, R., Fronzo, G. D., Valagussa, P.·1990·JNCI Journal of the National Cancer Institute

Abstract

In 165 women with breast cancer who were candidates for mastectomy because the largest diameter of the tumor was 3 cm or more, we administered primary chemotherapy in the attempt to substitute conservative for mutilating surgery. We then systematically quantitated tumor reduction by clinical, radiologic, and histopathologic evaluations. Five consecutive groups of 33 patients received cyclophosphamide, methotrexate, and fluorouracil (CMF); fluorouracil, doxorubicin (Adriamycin), and cyclophosphamide (FAC); or fluorouracil, epirubicin, and cyclophosphamide (FEC). The regimens for the five groups were as follows: group 1, three cycles of CMF; group 2, four cycles of CMF; group 3, three cycles of FAC; group 4, four cycles of FAC; and group 5, three cycles of FEC. In response to primary chemotherapy, 157 of the 161 assessable patients showed measurable tumor shrinkage; progressive disease was documented in four. Tumor shrinkage to less than 3 cm was documented in 127 (81%) of the 157 women subjected to surgery, thus allowing a breast-saving procedure, rather than modified radical mastectomy, in these 127 women. Histopathologic complete remission was documented in seven patients. Tumor response was unrelated to age, menopausal status, DNA content (ploidy), [3H]thymidine-labeling index, drug combination used, or number of treatment cycles in excess of three. The degree of response was inversely proportional to the initial tumor size, and the frequency of response was greater in receptor-negative tumors. Severe vomiting and hair loss were less frequent with CMF than with anthracycline-containing regimens, and the frequency of severe leukopenia and thrombocytopenia was minimal. Our results challenge the classical indication for primary mastectomy by showing that use of full-dose primary chemotherapy, sequentially combined with conservative surgery and radiation, can offer an effective and safe alternative to women concerned about the preservation of body integrity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/82.19.1539

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 607

Metadata

Authors
Bonadonna, G., Veronesi, U., Brambilla, C., Ferrari, L., Luini, A., Greco, M., Bartoli, C., Yoldi, G. C. D., Zucali, R., Rilke, F., Andreola, S., Silvestrini, R., Fronzo, G. D., & Valagussa, P.
Venue
JNCI Journal of the National Cancer Institute
Published
1990-10-03
Volume
82
Issue
19
Pages
1539-1545
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W2086766680
Cited by
607
References
0
FWCI
11.39
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Primary Chemotherapy To Avoid Mastectomy in Tumors With Diameters of Three Centimeters or More. https://app.cochat.ai/papers/10.1093/jnci/82.19.1539
The paper
Bonadonna, G., Veronesi, U., Brambilla, C., Ferrari, L., Luini, A., Greco, M., Bartoli, C., Yoldi, G. C. D., Zucali, R., Rilke, F., Andreola, S., Silvestrini, R., Fronzo, G. D., & Valagussa, P. (1990). Primary Chemotherapy To Avoid Mastectomy in Tumors With Diameters of Three Centimeters or More. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/82.19.1539

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.